Travere Therapeutics, Inc. 8-K

What Happened

• Travere Therapeutics, Inc. (NASDAQ: TVTX) filed a Form 8-K on January 12, 2026 (Item 2.02) announcing preliminary financial results for the fourth quarter and full year ended December 31, 2025.
• The company issued a press release with those preliminary results, which is attached to the 8-K as Exhibit 99.1. The report was signed by CEO Eric Dube.

Key Details

• Filing date: January 12, 2026.
• Reporting period: Fourth quarter and year ended December 31, 2025.
• Disclosure type: Preliminary results announced via press release (Exhibit 99.1) reported under Item 2.02 (Results of Operations and Financial Condition).
• Administrative: Exhibit and Interactive XBRL cover page included under Item 9.01; 8-K signed by Eric Dube, Chief Executive Officer.

Why It Matters

• Preliminary results give investors an early look at Travere’s earnings and revenue trends for Q4 and FY2025 and can influence short-term market reaction.
• Because the figures are preliminary, investors should review the attached press release for specifics and await the company’s final, audited results (e.g., in quarterly/annual filings) for confirmed numbers and further detail.